- Cyclotides: a patent review
[作者：Smith, AB; Daly, NL; Craik, DJ,期刊：Expert Opinion on Therapeutic Patents, 页码：1657-1672 , 文章类型： Review，,卷期：2011年21-11]
- Introduction: Cyclotides are bioactive mini-proteins from plants that have the unique topological feature of a head-to-tail cyclic backbone combined with a cystine knot. Because of this structure they are ultra-stable an...
- Selective PI3K delta inhibitors, a review of the patent literature
[作者：Norman, P,期刊：Expert Opinion on Therapeutic Patents, 页码：1773-1790 , 文章类型： Review，,卷期：2011年21-11]
- Introduction: Phosphatidylinositol 3-kinase (PI3K), a lipid kinase, is the first kinase involved in, and a key component of, the PI3K/Akt/mTOR signalling pathway, and is significantly upregulated in many cancers. However...
- 3-Hydroxy-6,7-dihydropyrimido [2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1
[作者：Cotelle, P,期刊：Expert Opinion on Therapeutic Patents, 页码：1799-1804 , 文章类型： Article，,卷期：2011年21-11]
- Since the discovery of raltegravir, the first FDA-approved integrase inhibitor, Merck and other pharmaceutical companies have continued their research programs in order to introduce novel molecules as second generation i...
- Novel 1,5-naphthyridine PI3K delta inhibitors, an evaluation of WO2011075628
[作者：Norman, P,期刊：Expert Opinion on Therapeutic Patents, 页码：1805-1810 , 文章类型： Article，,卷期：2011年21-11]
- A small series of aryl(1-arylamino) ethyl, 1,5-naphthyridine derivatives that selectively inhibit PI3K delta was prepared. The compounds are claimed to be useful in the treatment of cancer, inflammatory and autoimmune di...
|